FDA Grants Fast Track Designation To Lipocine's LPCN 1148 For Treating Sarcopenia In Patients With Decompensated Cirrhosis, Targeting First-In-Class Status With Novel Mechanism Of Action
FDA Grants Fast Track Designation To Lipocine's LPCN 1148 For Treating Sarcopenia In Patients With Decompensated Cirrhosis, Targeting First-In-Class Status With Novel Mechanism Of Action
FDA授予Lipocine的LPCN 1148在治療失代償性肝硬化患者的肌肉減少症方面快速通道認證，旨在通過新穎的作用機制實現首創藥物地位。
FDA Grants Fast Track Designation To Lipocine's LPCN 1148 For Treating Sarcopenia In Patients With Decompensated Cirrhosis, Targeting First-In-Class Status With Novel Mechanism Of Action
美國食品和藥物管理局授予Lipocine的LPCN 1148快速通道稱號，用於治療失代償性肝硬化患者的肌肉減少症，以新的作用機制爲目標，獲得同類首屈一指的目標
資訊熱榜
更新時間